Choose Your News
Loading...
* Editas medicine, inc. Announces pricing of $90 million offering of common stock... [Read More]
Allergan said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine's experimental gene-editing-based eye treatments under... [Read More]
Thumbnail
Allergan plc said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine Inc's experimental gene-editing-based eye... [Read More]
* Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases... [Read More]
* Entered into amendment to amended and restated CAS9*I license agreement with Harvard and Broad Institute. [Read More]
* Editas Medicine announces fourth quarter and full year 2016 results and update... [Read More]
* Editas medicine inc files for mixed shelf offering of up to $350 million - sec filing... [Read More]
Preview